Research Analysts Set Expectations for CRVS FY2030 Earnings

Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) – HC Wainwright issued their FY2030 earnings per share (EPS) estimates for Corvus Pharmaceuticals in a report released on Friday, March 13th. HC Wainwright analyst S. Lee forecasts that the company will earn $0.83 per share for the year. HC Wainwright currently has a “Buy” rating and a $27.00 target price on the stock. The consensus estimate for Corvus Pharmaceuticals’ current full-year earnings is ($0.63) per share.

Corvus Pharmaceuticals (NASDAQ:CRVS) last posted its quarterly earnings data on Thursday, March 12th. The company reported ($0.15) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.01).

Several other analysts also recently weighed in on the stock. Oppenheimer reaffirmed an “outperform” rating and issued a $33.00 target price (up from $32.00) on shares of Corvus Pharmaceuticals in a report on Friday. Barclays raised their price objective on shares of Corvus Pharmaceuticals from $16.00 to $28.00 and gave the company an “overweight” rating in a research report on Tuesday, January 20th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Corvus Pharmaceuticals in a report on Wednesday, January 21st. Wall Street Zen cut Corvus Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Saturday. Finally, Jefferies Financial Group increased their target price on Corvus Pharmaceuticals from $13.00 to $42.00 and gave the stock a “buy” rating in a research note on Thursday, January 22nd. Six research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $32.00.

Corvus Pharmaceuticals Stock Performance

Shares of Corvus Pharmaceuticals stock opened at $15.72 on Monday. Corvus Pharmaceuticals has a one year low of $2.54 and a one year high of $26.95. The company has a market cap of $1.32 billion, a P/E ratio of -31.44 and a beta of 0.79. The firm has a fifty day moving average of $16.64 and a two-hundred day moving average of $10.68.

Institutional Trading of Corvus Pharmaceuticals

Several hedge funds and other institutional investors have recently made changes to their positions in CRVS. Quarry LP acquired a new stake in shares of Corvus Pharmaceuticals in the third quarter valued at about $27,000. Mirae Asset Global Investments Co. Ltd. grew its position in Corvus Pharmaceuticals by 26.0% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,629 shares of the company’s stock worth $28,000 after buying an additional 748 shares during the period. Police & Firemen s Retirement System of New Jersey purchased a new position in Corvus Pharmaceuticals in the second quarter valued at about $49,000. Russell Investments Group Ltd. purchased a new position in Corvus Pharmaceuticals in the third quarter valued at about $49,000. Finally, Sender Co & Partners Inc. acquired a new stake in shares of Corvus Pharmaceuticals during the 2nd quarter valued at approximately $52,000. Institutional investors and hedge funds own 46.64% of the company’s stock.

Corvus Pharmaceuticals Company Profile

Corvus Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of next-generation immuno-oncology therapies. The company’s research efforts are centered on harnessing both the innate and adaptive immune systems to counteract tumor-driven immunosuppression. By targeting key pathways that regulate immune cell function, Corvus aims to create novel agents that can be combined with existing cancer treatments to improve patient outcomes.

Corvus’s lead pipeline candidates include small-molecule and antibody therapies designed to inhibit the adenosine pathway, a known mediator of tumor immune escape.